MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for First Quarter 2009 Financial and Operational Results
06 Aprile 2009 - 2:22PM
Business Wire
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) is scheduled to
announce its financial results for the 2009 first quarter on
Thursday, May 7, 2009, before the market opens. At 9:00 a.m. (ET)
on that day, MiddleBrook management will conduct a conference call
to review results for the 2009 first quarter.
To listen live to the call, dial 1-800-813-8504 or
1-660-422-4526. A replay of the call will be available starting at
approximately 11 a.m. on May 7 through 5 p.m. on May 14, 2009. To
listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and
enter the conference ID #94048404.
A live audio webcast of the conference call also will be
available by going to the Investor Relations section of
MiddleBrook's web site, www.middlebrookpharma.com. A replay of the
webcast will be available starting at approximately 11 a.m. on May
7 through 5 p.m. on June 5, 2009.
MiddleBrook Pharmaceuticals Reports Inducement
Grants Under NASDAQ Marketplace Rule 4350
MiddleBrook Pharmaceuticals also announced today that on March
31, 2009, it granted options to purchase 3,500 shares of
MiddleBrook's common stock to two (2) new employees as a material
inducement for them to join MiddleBrook. The options were granted
pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under
MiddleBrook's New Hire Stock Incentive Plan, which was approved by
MiddleBrook's Board of Directors on Sept. 26, 2008. The options
have a per share exercise price equal to the closing price of
MiddleBrook's common stock on the NASDAQ Global Market on the
business day immediately preceding the grant date, a ten-year term
and vesting over four years, with 25 percent of the options vesting
one year from the grant date and 1/48th of the options vesting
monthly thereafter. The options have a grant date of March 31,
2009.
About MiddleBrook
Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a
pharmaceutical company focused on developing and commercializing
anti-infective products that fulfill unmet medical needs. We have
developed a proprietary delivery technology called PULSYS, which
enables the pulsatile delivery, or delivery in rapid bursts, of
certain drugs. We are currently developing a portfolio of
anti-infective PULSYS products. Our near-term corporate strategy is
to improve dosing regimens and/or reduce frequency of dosing which
we believe will result in improved patient dosing convenience and
compliance for antibiotics that have been used and trusted by
physicians and patients for decades. MiddleBrook currently markets
KEFLEX, the immediate-release brand of cephalexin, and MOXATAG �
the first and only FDA-approved once-daily amoxicillin. For more
information about MiddleBrook, please visit
www.middlebrookpharma.com.
Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Mag 2023 a Mag 2024